Ribonucleic acid-based therapy for inflammation and arthritis:  LncRNA HOTAIRM1-1 (HOX antisense intergenic RNA myeloid 1 variant 1) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 3/March/2018, 6.41 am